Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Neuropeptide FF
Overview
Neuropeptide FF (NPFF) is an octapeptide belonging to the RFamide family, characterized by an arginine-phenylalanine-amide motif at the C-terminus. It acts on two G protein-coupled receptors, NPFF1 and NPFF2, and modulates opioid-induced analgesia, tolerance, and hyperalgesia.
Mechanism of Action
NPFF is widely distributed in the central nervous system and participates in pain modulation, opioid tolerance mechanisms, and cardiovascular regulation. Its dual role as both a pronociceptive and anti-opioid peptide has generated interest in targeting its receptors for chronic pain management.
Research Summary & Key Findings
Preclinical rodent studies have demonstrated that NPFF receptor antagonists can prevent or reverse opioid tolerance and opioid-induced hyperalgesia. NPFF receptor agonists have shown potential in modulating morphine withdrawal symptoms in animal models. No human clinical trials targeting NPFF receptors have been reported to date, and therapeutic development remains at the discovery stage.
Clinical Status
Neuropeptide FF is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Neuropeptide FF"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Neuropeptide FF"
Registered interventional and observational studies, including status and phase.
- PubChem: "Neuropeptide FF"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Pain
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone...
View detailsDifelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing periphera...
View detailsARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the inna...
View detailsPalmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to ti...
View detailsNo lawful pathway today
Neuropeptide FF is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.